Top

Published in:

01-03-2011 | Original Article

Markers of childhood lupus nephritis indicating disease activity

Authors: Monika Edelbauer, Sudhir Kshirsagar, Magdalena Riedl, Dieter Haffner, Heiko Billing, Burkhard Tönshoff, Sophia Ross, Jörg Dötsch, Oliver Amon, Henry Fehrenbach, Christian Steuber, Antje Beissert, Josef Hager, Gottfried Wechselberger, Lutz T. Weber, Lothar Bernd Zimmerhackl

Published in: Pediatric Nephrology | Issue 3/2011

Abstract

Current treatment regimens for childhood lupus nephritis (LN) are associated with significant side-effects and toxicity in vulnerable phases of growth and development. The paucity of biomarkers particularly in childhood impedes the appropriate clinical management and the development of new therapeutics. We analyzed markers of immune system (BAFF, RANTES), complement (Bb, C1q, C3d-CIC, C5a) and endothelial cell activation (sVCAM-1) in children with LN (n = 22, mean age 14.8 ± 4.7 years), nephrotic syndrome (n = 13) and age-matched healthy controls (n = 20) to define parameters that correlate with LN activity. Complement fragments of the alternative (Bb, p = 0.0004) classical (C3d-CIC, p < 0.0001) and common pathway (C5a, p < 0.0001) and the levels of BAFF (p < 0.0001), RANTES (p = 0.0002) and sVCAM-1 (p = 0.0004) were significantly higher in active compared to inactive LN. Activation of complement was associated with the occurrence of anti-C1q antibodies and reduced complement C1q. Complement-activation fragments highly correlated with the markers for immune system and endothelial cell activation. The ensemble of these parameters may be of great value in identifying early flares or remissions of childhood LN, and moreover may prove useful in the assessment of new treatments and in determining the optimization of their use.

Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF (2008) B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223:284–299PubMedCrossRef

Chu VT, Enghard P, Schurer S, Steinhauser G, Rudolph B, Riemekasten G, Berek C (2009) Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60:2083–2093PubMedCrossRef

Cancro MP, D'Cruz DP, Khamashta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 119:1066–1073PubMedCrossRef

Das L, Brunner HI (2009) Biomarkers for renal disease in childhood. Curr Rheumatol Rep 11:218–225PubMedCrossRef

Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C (2008) Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 10:R112PubMedCrossRef

Bao L, Quigg RJ (2007) Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol 27:69–80PubMedCrossRef

Seelen MA, Daha MR (2006) The role of complement in autoimmune renal disease. Autoimmunity 39:411–415PubMedCrossRef

Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058–1066PubMedCrossRef

Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG (1994) Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long-term prospective study. Clin Exp Immunol 97:439–444PubMedCrossRef

10.

Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO (1993) Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 92:412–418PubMedCrossRef

11.

Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431–456PubMedCrossRef

12.

Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76:227–324PubMedCrossRef

13.

Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA (1999) Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 42:187–188PubMedCrossRef

14.

Kozyro I, Korosteleva L, Chernoshej D, Danner D, Sukalo A, Trendelenburg M (2008) Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clin Immunol 128:409–414PubMedCrossRef

15.

Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Fremeaux-Bacchi V, Martinez-Ara J, Jancova E, Picazo ML, Honsova E, Tesar V, Sadallah S, Schifferli J (2006) High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 21:3115–3121PubMedCrossRef

16.

Merrill JT, Buyon JP (2005) The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol 19:709–726PubMedCrossRef

17.

Lefkowith JB, Gilkeson GS (1996) Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 39:894–903PubMedCrossRef

18.

Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 50:1709–1720PubMedCrossRef

19.

Valentijn RM, van Overhagen H, Hazevoet HM, Hermans J, Cats A, Daha MR, van EL (1985) The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 28:904–913PubMedCrossRef

20.

Hunsicker LG, Ruddy S, Carpenter CB, Schur PH, Merrill JP, Muller-Eberhard HJ, Austen KF (1972) Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med 287:835–840PubMedCrossRef

21.

Schur PH (1982) Complement and lupus erythematosus. Arthritis Rheum 25:793–798PubMedCrossRef

22.

Sturfelt G, Sjoholm AG (1984) Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 75:75–83PubMedCrossRef

23.

Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, Medsger TA Jr, Ramsey-Goldman R (1996) Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39:1178–1188PubMedCrossRef

24.

Ceribelli A, Andreoli L, Cavazzana I, Franceschini F, Radice A, Rimoldi L, Sinico RA, Carlsson M, Wieslander J, Tincani A (2009) Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways. Ann NY Acad Sci 1173:427–434PubMedCrossRef

25.

Jesus AA, Silva CA, Carneiro-Sampaio M, Sheinberg M, Mangueira CL, Marie SK, Liphaus BL (2009) Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus. Ann NY Acad Sci 1173:235–238PubMedCrossRef

26.

Wu YL, Higgins GC, Rennebohm RM, Chung EK, Yang Y, Zhou B, Nagaraja HN, Birmingham DJ, Rovin BH, Hebert LA, Yu CY (2006) Three distinct profiles of serum complement C4 proteins in pediatric systemic lupus erythematosus (SLE) patients: tight associations of complement C4 and C3 protein levels in SLE but not in healthy subjects. Adv Exp Med Biol 586:227–247PubMedCrossRef

27.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef

28.

Ferraz MB, Goldenberg J, Hilario MO, Bastos WA, Oliveira SK, Azevedo EC, di Napoli D (1994) Evaluation of the 1982 ARA lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology. Clin Exp Rheumatol 12:83–87PubMed

29.

Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250PubMedCrossRef

30.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef

31.

Brunner HI, Feldman BM, Bombardier C, Silverman ED (1999) Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 42:1354–1360PubMedCrossRef

32.

Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed

33.

Gladman DD, Urowitz MB, Kagal A, Hallett D (2000) Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 27:377–379PubMed

34.

Rahman P, Gladman DD, Ibanez D, Urowitz MB (2001) Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Lupus 10:418–423PubMedCrossRef

35.

Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458PubMed

36.

Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, Haines KA, Onel K, O'Neil K, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI (2009) Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 60:2772–2781PubMedCrossRef

37.

Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, Pego-Reigosa JM, Lu TY, Isenberg D, Rahman A, Putterman C (2010) Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 49:960–971CrossRef

38.

Marks SD, Shah V, Pilkington C, Tullus K (2010) Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol 25:2283–2288PubMedCrossRef

39.

Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M (2009) Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol 183:3512–3521PubMedCrossRef

40.

Davies KA, Peters AM, Beynon HL, Walport MJ (1992) Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 90:2075–2083PubMedCrossRef

41.

Truedsson L, Bengtsson AA, Sturfelt G (2007) Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40:560–566PubMedCrossRef

42.

Castellano G, Woltman AM, Nauta AJ, Roos A, Trouw LA, Seelen MA, Schena FP, Daha MR, van Kooten C (2004) Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 103:3813–3820PubMedCrossRef

43.

Kaul M, Loos M (2001) Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-gamma. FEBS Lett 500:91–98PubMedCrossRef

44.

Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294:1540–1543PubMedCrossRef

45.

Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr (2005) Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 64:1692–1697PubMedCrossRef

46.

Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54:2951–2962PubMedCrossRef

47.

Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS (2004) Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int 65:129–138PubMedCrossRef

48.

Vieyra MB, Heeger PS (2010) Novel aspects of complement in kidney injury. Kidney Int 77:495–499PubMedCrossRef

49.

Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276–286PubMedCrossRef

50.

Muso E, Sekita K, Doi T, Kuwahara T, Yoshida H, Tamura T, Kawai C, Hamashima Y (1984) Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis. Clin Immunol Immunopathol 32:351–358PubMedCrossRef

51.

Wenderfer SE, Ke B, Hollmann TJ, Wetsel RA, Lan HY, Braun MC (2005) C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol 16:3572–3582PubMedCrossRef

52.

Wittmann M, Zwirner J, Larsson VA, Kirchhoff K, Begemann G, Kapp A, Gotze O, Werfel T (1999) C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol 162:6763–6769PubMed

53.

Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ (2005) C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 35:2496–2506PubMedCrossRef

54.

Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ (2003) Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol 14:670–679PubMedCrossRef

55.

David S, Biancone L, Caserta C, Bussolati B, Cambi V, Camussi G (1997) Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol Dial Transplant 12:51–56PubMedCrossRef

56.

Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A, Bundred NJ (2000) Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 92:1329–1336PubMedCrossRef

57.

Nakatani K, Fujii H, Hasegawa H, Terada M, Arita N, Ito MR, Ono M, Takahashi S, Saiga K, Yoshimoto S, Iwano M, Shiiki H, Saito Y, Nose M (2004) Endothelial adhesion molecules in glomerular lesions: association with their severity and diversity in lupus models. Kidney Int 65:1290–1300PubMedCrossRef

58.

Seron D, Cameron JS, Haskard DO (1991) Expression of VCAM-1 in the normal and diseased kidney. Nephrol Dial Transplant 6:917–922PubMed

59.

Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444PubMedCrossRef

Title: Markers of childhood lupus nephritis indicating disease activity
Authors: Monika Edelbauer
Sudhir Kshirsagar
Magdalena Riedl
Dieter Haffner
Heiko Billing
Burkhard Tönshoff
Sophia Ross
Jörg Dötsch
Oliver Amon
Henry Fehrenbach
Christian Steuber
Antje Beissert
Josef Hager
Gottfried Wechselberger
Lutz T. Weber
Lothar Bernd Zimmerhackl
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 3/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-010-1720-x

At a glance: The STEP trials

Springer Medicine

Markers of childhood lupus nephritis indicating disease activity

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Hepatic and pulmonary nodular lesions in pediatric urinary tract infections

Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children

Fatal renal failure caused by Cortinarius mushrooms

Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study

Expression and function of the Ets transcription factor pea3 during formation of zebrafish pronephros

World Kidney Day 2011: Protect your kidneys, save your heart